Pharma Pulse 6/17/24: Pet Care Industry Eyes GLP-1s, Improving Quality of Care for Cancer Patients & more
Improving Quality of Care for Cancer Patients
In fourth and final part of this video interview, Marc Buyse, founder, and Sebastien Coppe, CEO; both of One2Treat emphasize the importance of personalizing oncology studies and giving patients more choices.
Why We Can’t Give Up on Value-Based Care | AHIP 2024
Scott Burton, MBA, commercial market president at Providence Health Plan said that 65% of Providence’s commercial claims are running through some kind of value-based contract. “That is progress — that is meaningful progress,” Burton said in an interview with Managed Healthcare Executive.
Improve Site Experience with Data-Driven Protocol Design
Sites can encounter a wide range of challenges when operationalizing study protocols, including the need to manage frequent and lengthy patients visits, coordinate complicated procedure schedules and utilize multiple disparate technology systems. Applied analytics enable data-driven protocol design that can help sponsors mitigate these trial challenges.
Data collected from sites can help uncover specific protocol elements that drive sites’ perception of burden. These findings can be used to optimize protocol design to decrease burden and improve site experience, potentially leading to positive outcomes such as facilitating the collection of cleaner data and improving protocol compliance.
Pet Care Industry Is Dreaming of Dog and Cat Ozempic
Companies are jumping into the red-hot GLP-1 market with a surprising new target: pets. But first...
Collaboration aims to accelerate speed to diagnosis and treatment of hypertrophic cardiomyopathy.
In this Pharmaceutical Commerce Magazine article by Suzanne Shelley (she/her), our experts Amanda Bruno and Angela W. share the importance of using real-world data to inform patient-focused outreach. Read the full article: https://lnkd.in/gkxCfxst #SyneosHealth
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
